 | Up a level |
Liam, Chong Kin and Ahmad, Azura Rozila and Hsia, Te-Chun and Zhou, Jianying and Kim, Dong-Wan and Soo, Ross Andrew and Cheng, Ying and Lu, Shun and Shin, Sang Won and Yang, James Chih-Hsin and Zhang, Yiping and Zhao, Jun and Berghoff, Karin and Bruns, Rolf and Johne, Andreas and Wu, Yi-Long (2023) Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical Cancer Research, 29 (10). pp. 1879-1886. ISSN 1078-0432, DOI https://doi.org/10.1158/1078-0432.CCR-22-3318.
Ahn, Myung-Ju and Mendoza, Marvin Jonne L. and Pavlakis, Nick and Kato, Terufumi and Soo, Ross A. and Kim, Dong-Wan and Liam, Chong Kin and Hsia, Te-Chun and Lee, Chee Khoon and Reungwetwattana, Thanyanan and Geater, Sarayut and Chan, Oscar Siu Hong and Prasongsook, Naiyarat and Solomon, Benjamin J. and Nguyen, Thi Thai Hoa and Kozuki, Toshiyuki and Yang, James Chih-Hsin and Wu, Yi-Long and Kam, Tony Shu and Tan, Daniel Shao-Weng and Yatabe, Yasushi (2022) Asian Thoracic Oncology Research Group (ATORG) expert consensus statement on MET alterations in NSCLC: Diagnostic and therapeutic considerations. CLINICAL LUNG CANCER, 23 (8). pp. 670-685. ISSN 1938-0690, DOI https://doi.org/10.1016/j.cllc.2022.07.012.
